# US 2022/0008526 A1 · Methods and compositions for cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008526 A1
- Document ID: US20220008526A1
- Status: Published application
- Kind: A1
- Application number: 17/293,995
- Filed: 2019-11-15
- Published: 2022-01-13
- Earliest claimed: 2018-11-15
- Assignees: Torque Therapeutics, Inc.
- Applicants: Torque Therapeutics, Inc.
- Inventors: Thomas Lars Andresen; Douglas Jones; Elena Geretti; Gulzar Ahmad
- Web page: https://patentgrep.com/patent/US20220008526A1

## CPC

- C07K 14/54: Interleukins [IL]
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 38/20: Interleukins [IL]
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4234: {Interleukins [IL]}
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 35/00: Antineoplastic agents
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/289: {against CD45}
- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/6006: {Cells}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for cancer immunotherapy, and more particularly immune cells loaded with protein clusters and/or immunostimulatory fusion molecules (IFMs), in combination with an inhibitor of a checkpoint inhibitor.

## Claims

### Claim 1

A composition comprising:
a nucleated cell loaded with a plurality of protein clusters and/or immunostimulatory fusion molecules (IFMs); and
an inhibitor of a checkpoint inhibitor;
wherein each protein cluster comprises a plurality of therapeutic protein monomers reversibly cross-linked to one another via a plurality of biodegradable cross-linkers, wherein the protein cluster has a size between 30 nm and 1000 nm in diameter measured by dynamic light scattering, wherein the cross-linker degrades, after administration into a subject in need thereof, under physiological conditions so as to release the therapeutic protein monomers from the protein cluster, wherein optionally the protein cluster further comprises a surface modification such as polycation so as to allow the protein cluster to associate with the nucleated cell;
wherein each IFM is engineered to contain an immunostimulatory cytokine molecule and a targeting moiety (e.g., an antibody or an antigen-binding fragment thereof) having an affinity to an antigen on the surface of the nucleated cell, wherein the immunostimulatory cytokine molecule is operably linked to targeting moiety.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the nucleated cell is from a population of T cells that have been enriched or trained to possess specificity against one or more tumor-associated antigens (TAAs).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the nucleated cell is substantially purified.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the nucleated cell is autologous to a subject in need of the composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the therapeutic protein monomers include one or more cytokine molecules and optionally one or more costimulatory molecules, wherein:
(i) the one or more cytokine molecules are selected from IL-15, IL-2, IL-7, IL-10, IL-12, IL-18, IL-21, IL-23, IL-4, IL-1alpha, IL-1beta, IL-5, IFNgamma, TNFa, IFNalpha, IFNbeta, GM-CSF, or GCSF; and
(ii) the one or more costimulatory molecules are selected from CD137, OX40, CD28, GITR, VISTA, anti-CD40 antibody, or CD3.

### Claim 6 (depends on 1)

The composition of claim 1, wherein in the IFM, the immunostimulatory cytokine molecule is selected from one or more of IL-15, IL-2, IL-6, IL-7, IL-12, IL-18, IL-21, IL-23, or IL-27 or variant forms thereof, and wherein the antigen is selected from one or more of CD45, CD4, CD8, CD3, CD11a, CD11b, CD11c, CD18, CD25, CD127, CD19, CD20, CD22, HLA-DR, CD197, CD38, CD27, CD196, CXCR3, CXCR4, CXCR5, CD84, CD229, CCR1, CCR5, CCR4, CCR6, CCR8, CCR10, CD16, CD56, CD137, OX40, or GITR.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the checkpoint inhibitor is one or more of PD-1, PD-L1, LAG-3, TIM-3, or CTLA-4.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the inhibitor of the checkpoint inhibitor is an antibody or antigen-binding fragment thereof that binds and neutralizes or inhibits the checkpoint inhibitor.

### Claim 9

A method for providing cancer immunotherapy, comprising:
administering to a patient in need thereof a plurality of nucleated cells loaded with a plurality of protein clusters and/or immunostimulatory fusion molecules (IFMs); and
administering to the patient an inhibitor of a checkpoint inhibitor;
wherein each protein cluster comprises a plurality of therapeutic protein monomers reversibly cross-linked to one another via a plurality of biodegradable cross-linkers, wherein the protein cluster has a size between 30 nm and 1000 nm in diameter measured by dynamic light scattering, wherein the cross-linker degrades, after administration into a subject in need thereof, under physiological conditions so as to release the therapeutic protein monomers from the protein cluster, wherein optionally the protein cluster further comprises a surface modification such as polycation so as to allow the protein cluster to associate with the nucleated cell;
wherein each IFM is engineered to contain an immunostimulatory cytokine molecule and a targeting moiety (e.g., an antibody or an antigen-binding fragment thereof) having an affinity to an antigen on the surface of the nucleated cell, wherein the immunostimulatory cytokine molecule is operably linked to targeting moiety.

### Claim 10 (depends on 9)

The method of claim 9, wherein the nucleated cell is substantially purified.

### Claim 11 (depends on 9)

The method of claim 9, wherein the nucleated cell is autologous to a subject in need of the composition.

### Claim 12 (depends on 9)

The method of claim 9, further comprising administering the nucleated cell and the inhibitor of checkpoint inhibitor separately.

### Claim 13 (depends on 9)

The method of claim 9, further comprising administering the nucleated cell and the inhibitor of checkpoint inhibitor sequentially.

### Claim 14 (depends on 9)

The method of claim 9, wherein the nucleated cell is from a population of T cells that have been enriched or trained to possess specificity against one or more tumor-associated antigens (TAAs).

### Claim 15 (depends on 9)

The method of claim 9, wherein the therapeutic protein monomers include one or more cytokine molecules and optionally one or more costimulatory molecules, wherein:
(i) the one or more cytokine molecules are selected from IL-15, IL-2, IL-7, IL-10, IL-12, IL-18, IL-21, IL-23, IL-4, IL-1alpha, IL-1beta, IL-5, IFNgamma, TNFa, IFNalpha, IFNbeta, GM-CSF, or GCSF; and
(ii) the one or more costimulatory molecules are selected from CD137, OX40, CD28, GITR, VISTA, anti-CD40 antibody, or CD3.

### Claim 16 (depends on 9)

The method of claim 9, wherein in the IFM, the immunostimulatory cytokine molecule is selected from one or more of IL-15, IL-2, IL-6, IL-7, IL-12, IL-18, IL-21, IL-23, or IL-27 or variant forms thereof, and wherein the antigen is selected from one or more of CD45, CD4, CD8, CD3, CD11a, CD11b, CD11c, CD18, CD25, CD127, CD19, CD20, CD22, HLA-DR, CD197, CD38, CD27, CD196, CXCR3, CXCR4, CXCR5, CD84, CD229, CCR1, CCR5, CCR4, CCR6, CCR8, CCR10, CD16, CD56, CD137, OX40, or GITR.

### Claim 17 (depends on 9)

The method of claim 9, wherein the checkpoint inhibitor is one or more of PD-1, PD-L1, LAG-3, TIM-3, or CTLA-4.

### Claim 18 (depends on 9)

The method of claim 9, wherein the inhibitor of the checkpoint inhibitor is an antibody or antigen-binding fragment thereof that binds and neutralizes or inhibits the checkpoint inhibitor.
